L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
Fluoxetine and L-deprenyl were prescribed concurrently in a 19-year-old female with Huntington's disease. The patient showed significant affective, behavioral, and motoric improvements and there was no adverse effect resulting from this combination. Concomitant use of L-deprenyl in low doses and fluoxetine may be safe and beneficial in certain clinical situations, although further study is needed.
Patel
S V
SV
Department of Psychiatry, Monroe Community Hospital, University of Rochester School of Medicine and Dentistry, New York 14620, USA.
Tariot
P N
PN
Asnis
J
J
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001288:Attention / Q000187:drug effects; D002220:Carbamazepine / Q000627:therapeutic use; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D019260:Expressed Emotion / Q000187:drug effects*; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D006816:Huntington Disease / Q000150:complications / Q000188:drug therapy*; D007175:Impulsive Behavior / Q000150:complications / Q000188:drug therapy; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D009068:Movement / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use*; D014754:Violence
D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D008996:Monoamine Oxidase Inhibitors; D005473:Fluoxetine; D012642:Selegiline; D002220:Carbamazepine